BACKGROUND: Neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer offers theoretical advantages over the standard approach of surgery followed by adjuvant CRT. We hypothesized that histological responses to CRT would be significant prognostic factors in patients undergoing neoadjuvant CRT followed by resection. METHODS: Since 1994, 193 patients with biopsy-proven pancreatic adenocarcinoma have completed neoadjuvant CRT, and 70 patients have undergone resection. Specimens were retrospectively examined by an individual pathologist for histological responses (tumor necrosis, tumor fibrosis, and residual tumor load) and immunohistochemical staining for p53 and epidermal growth factor receptor. Factors influencing overall survival were analyzed with the Kaplan-Meier (univariate) and Cox proportional hazards (multivariate) methods. RESULTS: The estimated overall survival (median +/- SE) in the entire group of patients undergoing resection was 23 +/- 4.2 months, with an estimated 3-year survival of 37% +/- 6.6% and a median follow-up of 28 months. Complete histological responses occurred in 6% of patients. Overexpression of p53 was more common in patients with large residual tumor loads. Tumor necrosis was an independent negative prognostic factor, as were positive lymph nodes, a large residual tumor load, and poor tumor differentiation. CONCLUSIONS: Histological response to neoadjuvant CRT--as measured by residual tumor load--may be useful as a surrogate marker for treatment efficacy. Characterization of the tumor cells that survive neoadjuvant CRT may help us to identify new or more appropriate targets for systemic therapy.
BACKGROUND: Neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer offers theoretical advantages over the standard approach of surgery followed by adjuvant CRT. We hypothesized that histological responses to CRT would be significant prognostic factors in patients undergoing neoadjuvant CRT followed by resection. METHODS: Since 1994, 193 patients with biopsy-proven pancreatic adenocarcinoma have completed neoadjuvant CRT, and 70 patients have undergone resection. Specimens were retrospectively examined by an individual pathologist for histological responses (tumor necrosis, tumor fibrosis, and residual tumor load) and immunohistochemical staining for p53 and epidermal growth factor receptor. Factors influencing overall survival were analyzed with the Kaplan-Meier (univariate) and Cox proportional hazards (multivariate) methods. RESULTS: The estimated overall survival (median +/- SE) in the entire group of patients undergoing resection was 23 +/- 4.2 months, with an estimated 3-year survival of 37% +/- 6.6% and a median follow-up of 28 months. Complete histological responses occurred in 6% of patients. Overexpression of p53 was more common in patients with large residual tumor loads. Tumor necrosis was an independent negative prognostic factor, as were positive lymph nodes, a large residual tumor load, and poor tumor differentiation. CONCLUSIONS: Histological response to neoadjuvant CRT--as measured by residual tumor load--may be useful as a surrogate marker for treatment efficacy. Characterization of the tumor cells that survive neoadjuvant CRT may help us to identify new or more appropriate targets for systemic therapy.
Authors: Charles C Hsu; Christopher L Wolfgang; Daniel A Laheru; Timothy M Pawlik; Michael J Swartz; Jordan M Winter; Raymond Robinson; Barish H Edil; Amol K Narang; Michael A Choti; Ralph H Hruban; John L Cameron; Richard D Schulick; Joseph M Herman Journal: J Gastrointest Surg Date: 2012-02-07 Impact factor: 3.452
Authors: Susan Tsai; Michael A Choti; Lia Assumpcao; John L Cameron; Ana L Gleisner; Joseph M Herman; Frederic Eckhauser; Barish H Edil; Richard D Schulick; Christopher L Wolfgang; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2010-04-30 Impact factor: 3.452
Authors: Edward F Jackson; Emilio Esparza-Coss; Xiaoxia Wen; Chaan S Ng; Sherita L Daniel; Roger E Price; Belinda Rivera; Chusilp Charnsangavej; Juri G Gelovani; Chun Li Journal: Int J Radiat Oncol Biol Phys Date: 2007-03-26 Impact factor: 7.038
Authors: Dominik Tinkl; Gerhard G Grabenbauer; Henriette Golcher; Thomas Meyer; Thomas Papadopoulos; Werner Hohenberger; Rolf Sauer; Thomas B Brunner Journal: Strahlenther Onkol Date: 2009-09-12 Impact factor: 3.621